CTNNB1 and neoplasm: During or after neoadjuvant chemotherapy, 33–36% (5/15 to 5/14, as one case was lacking tumor CTNNB1-mutation confirmation with Sanger sequencing) of samples had detectable CTNNB1 variants, with a mean VAF of 3.5% (ranging from 0.3% to 6.3%).